GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tyra Biosciences TYRA · USD

Health Care · US listing · 🇺🇸 United States

Compare

22.30

+5.44%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$119.9m

FY2019FY2025

Free cash flow

−$95.3m

FY2019FY2025

Shareholders' equity

$259.2m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross profit−$546,000−$519,000−$353,000−$296,000−$140,000−$47,000−$8,000
Research and development$102.9m$80.1m$62.5m$43.0m$20.6m$7.2m$1.8m
Operating income−$132.8m−$104.2m−$79.9m−$58.9m−$26.3m−$9.3m−$3.1m
Net income−$119.9m−$86.5m−$69.1m−$51.7m−$26.1m−$9.3m−$4.1m
Diluted earnings per share-2.01-1.47-1.61-1.23-0.63-0.41-0.10

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$282.6m$363.6m$225.9m$266.2m$306.7m$16.0m$528,000
Cash and short-term investments$256.0m$341.4m$203.5m$251.2m$302.2m$15.2m$108,000
Total liabilities$23.4m$20.4m$21.6m$8.4m$5.0m$29.6m$5.3m
Shareholders' equity$259.2m$343.2m$204.3m$257.8m$301.7m−$13.6m−$4.7m
Shares outstanding60m59m43m42m41m22m43m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$95.1m−$69.8m−$50.1m−$50.3m−$23.7m−$7.8m−$2.6m
Capital spending−$141,000−$664,000−$770,000−$559,000−$661,000−$312,000−$20,000
Free cash flow−$95.3m−$70.4m−$50.9m−$50.8m−$24.4m−$8.1m−$2.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$496,000—
Gross profit—−$138,000−$132,000—−$140,000−$143,000$248,000−$127,000
Operating income−$49.0m−$42.0m−$36.5m−$32.9m−$31.5m−$31.9m−$29.7m−$28.6m
Net income−$45.6m−$39.3m−$33.8m−$29.9m−$28.1m−$28.1m−$25.6m−$24.0m
Diluted earnings per share-0.69-0.60-0.57-0.50-0.47-0.47-0.43-0.41
Cash from operations−$31.0m−$32.0m−$23.0m−$22.0m−$23.0m−$25.0m−$19.0m−$17.0m
Total assets$383.4m$412.0m$282.6m$301.9m$321.5m$343.5m$363.6m$380.6m
Cash and short-term investments$353.9m$383.5m$256.0m$274.9m$296.3m$318.9m$341.4m$360.1m
Debt$504,000$488,000$472,000$456,000$441,000$426,000$412,000$398,000
Shareholders' equity$353.7m$387.6m$259.2m$280.5m$302.1m$323.5m$343.2m$362.3m

Financial ratios

Data as of 30 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on equity-46.3%-25.2%-33.8%-20.1%-8.7%68.3%—
Return on assets-42.4%-23.8%-30.6%-19.4%-8.5%-58.2%—
Free cash flow yield-7.4%-5.5%-5.3%-5.5%-2.6%-1.5%—
Earnings growth38.7%25.1%33.7%97.9%180.7%129.5%—
Current ratio14.67x23.81x13.80x45.13x84.09x8.22x—
Debt to equity0.00x0.00x0.00x0.00x0.00x-0.01x—
Equity ratio91.7%94.4%90.4%96.9%98.4%-85.2%—
Interest coverage———-199.08x-187.77x-9297.00x-3122.00x
Buybacks as a share of market value-1.2%-37.0%-1.8%-2.2%-83.7%——

Growth per year

Compound annual rate

3 years5 years10 years
Operating income31.1%70.1%—
Net income32.4%66.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-13.1-9.5-8.6-6.2-22.2

Market value over time

30 Sept 2021 to 29 Oct 2026, in USD

$158.3m$1.42bn

Share price return

Finished calendar years

20252024202320222021
Return58%2%102%-43%-53%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.